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The expanded ability to detect myocardial injury using very sensi-
tive and speciﬁc biomarker assays has been a major factor in the
evolution of the deﬁnition of acute myocardial infarction (MI).
This is clearly evident in the ‘Universal Deﬁnition of Myocardial
Infarction’ recently developed by a joint task force of experts on
behalf of the ESC, ACCF, AHA, and WHF (European Society of
Cardiology, American College of Cardiology Foundation, Ameri-
can Heart Association, and World Heart Federation).
1 In a clinical
setting consistent with myocardial ischaemia, criteria are presented
for deﬁning acute MI that include a rise and/or fall in cardiac bio-
markers together with symptoms of ischaemia, and/or appropriate
ECG changes, and/or imaging evidence of a new regional wall
motion abnormality or loss of myocardium. The task force devel-
oped a clinical classiﬁcation of different types of MI that can be
brieﬂy summarized as:
TYPE 1: MI due to a spontaneous coronary atherosclerotic event.
TYPE 2: MI secondary to ischaemia, but not related to coronary
atherosclerosis.
TYPE 3: Sudden death with symptoms or signs of ischaemia (not
requiring elevated biomarker conﬁrmation).
TYPE 4: MI associated with percutaneous coronary intervention
(Subtype 4a), or stent thrombosis (Subtype 4b).
TYPE 5: MI associated with coronary bypass surgery.
This multi-component scheme appears to add complexity in an
area that can be quite confounding because of the multiple
terms used to describe myocardial ischaemia/infarction in all of
its various manifestations. This includes differentiating myocardial
damage associated with ST elevation (STEMI) from that occurring
without ST elevation (non-STEMI). Patients with a sudden change
in cardiac status are often admitted to the hospital with a
diagnosis of acute coronary syndrome (ACS), but ACS is not
included in the ICD-9-CM codes.
2 Intermediate coronary
syndrome (code 411.1), which includes impending infarction,
preinfarction angina, or unstable angina, can be used as a substi-
tute for ACS.
How the new deﬁnitions of MI become incorporated into future
revisions of the ICD codes remains to be determined. Meanwhile,
understanding the basis for this classiﬁcation can help physicians
struggling to assess clinical data and develop appropriate diagnoses
for cardiac patients. A key concept incorporated into this scheme
is that cardiac biomarkers must be interpreted in clinical context.
This can be illustrated by considering a case example involving
the common problem of interpreting cardiac biomarkers in
patients hospitalized for serious non-cardiac diseases.
Our example patient was admitted to the medical intensive care
unit with shortness of breath due to acute pneumonia complicating
severe chronic obstructive pulmonary disease (COPD). A transient
elevation of troponin to a level three times the upper limits of
normal occurred following a period of hypotension and hypoxia
while he was septic. He had constant diffuse chest pains since he
ﬁrst felt ill, and his ECG showed atrial ﬁbrillation with lateral
T wave inversion, unchanged from prior ECGs. His shortness of
breath was attributed to his pulmonary disease, and no coronary
intervention performed. He recovered to where he could be dis-
charged, and further cardiac evaluation was deferred to the
*Corresponding author. Tel: þ1 612 467 3670, Fax: þ1 612 970 5899, Email: pierp002@umn.edu
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
Published by Oxford University Press on behalf of the European Society of Cardiology 2008.
The onlineversion of this article has been published underan open accessmodel. Usersare entitled to use, reproduce,disseminate, ordisplay the open accessversion of this article for
non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original
place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be
clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
European Heart Journal (2009) 30, 135–138
doi:10.1093/eurheartj/ehn517discretion of his primary care provider following further recovery
from his acute illness. The problem is how best to describe the
episode for purposes of documentation and subsequent follow-up.
There is no ICD-9 code to document myocardial injury (as evi-
denced by transient elevations in cardiac biomarkers) that occurs
because of severe extra-cardiac problems such as sepsis, but
according to the new Universal Deﬁnition of MI, this can be
called a TYPE 2 MI. Having this diagnosis available is a deﬁnitive
improvement compared with the 2000 ESC/ACC consensus on
redeﬁnition of MI.
3 The 2000 document stated that ‘any amount
of myocardial necrosis caused by ischaemia should be labeled as
MI’. This statement implied that a typical rise and fall of troponin
alone was adequate to make the diagnosis of acute, evolving, or
recent MI. In the ﬁnal (2000) summary, it was stated that the
rise and fall in biomarkers should be accompanied by at least
one additional ﬁnding (symptoms, ECG changes, or imaging ﬁnd-
ings as noted above). However, this inconsistency left an open
question as to when a transient biomarker elevation such as that
just described constitutes an MI, and what to label it if it is not
an MI.
In this patient, TYPE 2 MI would be a ‘working diagnosis’, as a
coronary lesion was not totally excluded. This lack of certainty is
often a source of discomfort when caring for ICU patients with
troponin elevation in association with concomitant disease. We
are not totally comfortable using symptoms as a major guide in
patients who are intubated, or sedated, or under the
intra-operative or post-operative effects of anaesthesia. We
know that ECG changes can be transient and can be missed
when observation is limited to a monitoring lead, or in the pre-
sence of signiﬁcant baseline abnormalities such as a paced ventricu-
lar rhythm, left bundle branch block, or pre-existing ST–T
abnormalities. We know that severe stress alone can cause bio-
marker release, but are also concerned about missing a signiﬁcant
coronary event. Moreover, ICU patients with severe non-cardiac
problems often have relative contra-indications to anticoagulants,
or cardiac catheterization and intervention. Non-invasive evalu-
ation can also be limited in such patients, and even if cardiac cathe-
terization is performed, coronary angiography cannot always
differentiate whether or not the episode involved an acute coron-
ary event or represented injury induced in the presence of signiﬁ-
cant but stable underlying coronary disease.
4 Finally, it is entirely
possible that both can be occurring at the same time, with the mul-
tiple stresses and pro-coagulants present in a severely ill patient
causing acute progression of coronary lesions (TYPE 1) concomi-
tant with cell damage from hypoxia or hypo-perfusion of non-
coronary aetiology (TYPE 2).
Despite these problems in clinical decision-making and patient
management, this case illustrates the advantages to having the diag-
nosis of TYPE 2 MI available. In discussing the Universal Deﬁnition
for MI, the joint commission discussed the importance of also
deﬁning the extent or severity of the MI. Based on the relatively
small rise in troponin and non-speciﬁc abnormalities on ECG,
the amount of cardiac damage in this patient was felt to be
small, and additional imaging studies to conﬁrm that assessment
were deferred. But the term TYPE 2 MI is still applicable, even
though we may qualify the diagnosis using appropriate modiﬁers
(such as possible or probable) with the recognition that the
diagnosis may be conﬁrmed, excluded, or further reﬁned, depend-
ing on further studies.
The Diagnosis of TYPE 2 MI is advantageous not only for docu-
mentation purposes, but can also assist in quality review programs.
Criteria for optimal care of acute MI often include measures such
as time from onset of symptoms to ﬁrst medical contact, time to
ﬁrst ECG, time from initial diagnosis to cardiac consultation, or
time from diagnosis to lytic therapy, arrival in the catheterization
lab, or reperfusion. Such measures are meaningless in patients
such as the one presented here, and using an alternate diagnosis
will prevent misclassiﬁcation of the event.
An additional advantage of the new terminology should be rea-
lized in epidemiological applications. Biomarkers are often used to
help predict prognosis, and most prognostic tools to predict long-
term outcome post-MI focus on indices of acute myocardial
damage, combined with presence/absence of well-established risk
factors. In cases of TYPE 2 MI, the prognosis is most likely
altered signiﬁcantly by the nature and severity of the illness preci-
pitating the biomarker elevation. As such, how biomarker data are
used in prognostic algorithms will likely differ for TYPE 1 com-
pared with TYPE 2 MI, and a clear distinction is needed.
When making the diagnosis of TYPE 2 MI, the extreme sensi-
tivity of troponin for detecting myocardial injury/infarction makes
it imperative to place all results in clinical perspective. It is well
recognized that troponin levels can be abnormal in the absence
of symptoms, ECG changes, or any gross evidence of myocardial
dysfunction or subsequent damage. Indeed, transient troponin
elevations into the abnormal range can be detected in approxi-
mately one-quarter
5,6 to one-third
7,8 of athletes at the end of a
marathon, with no evident functional consequences.
8 However,
unlike in the healthy athlete, even when biomarker elevations in
seriously ill patients are relatively small, they cannot be ignored.
Elevated troponin values can identify critically ill patients with a
worse prognosis,
9–13 and this ﬁnding extends to vascular surgery
patients who have perioperative troponin elevations.
14 Indeed,
prognosis may be worse for patients having troponin elevation
without other evidence of MI compared with those with
TYPE 1 MI.
4,15
Assessing troponin elevations in sick patients can also be com-
plicated because chronic, low-level elevations in troponin have
been documented in stable patients with renal failure, heart
failure, left ventricular hypertrophy, and diabetes mellitus,
16 and
the list of causes of elevated troponin appears to be growing.
17
These diagnoses are common in intensive care units, and it is
clear that a single elevated troponin requires a comparison to
baseline, with follow-up to determine its relative stability.
Multiple advantages of using the diagnosis of TYPE 2 MI are
evident, but are the diagnostic criteria optimal? TYPE 2 MI ﬁts as
a diagnosis for our example patient because the troponin elevation
was felt to be due to the episode of hypoxia and hypotension,
rather than a new plaque rupture/erosion/dissection/ or ﬁssuring
(TYPE 1 MI). Unfortunately, TYPE 2 is not speciﬁc to non-coronary
myocardial injury, because it also includes MI caused by coronary
spasm or embolism. Although not related to atherosclerotic
plaque, both spasm and embolism are coronary events and have
more in common with a ruptured plaque than with myocardial
injury induced by hypoxia, hypotension, myocarditis, etc. It
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coronary event from a non-coronary source of myocardial
damage, especially when assessing the need for urgent therapy
or intervention. In our case, for example, the atrial ﬁbrillation
provides a potential source of emboli. If a new coronary occlusion
is strongly suspected, it would be quite difﬁcult to know whether it
is thrombotic or embolic in origin, even by coronary angiography.
The indications for anticoagulation and/or invasive intervention
would likely be similar in either case, but not necessarily so if
hypotension and hypoxia were the culprit.
The non-descriptive nature of the term TYPE 2 MI is also of
concern. Biomarker release from the heart in the absence of a
new coronary event has been recognized for some time. The
ACC/AHA guidelines for management of unstable angina/
non-ST-elevation MI used ‘secondary UA’ to describe enzyme
elevation precipitated by a condition extrinsic to the coronary
arterial bed. Since angina may not be present, this appears to be
a less desirable alternative. ‘Non-speciﬁc troponin elevation’ and
‘non-thrombotic troponin elevation’
15 as well as ‘troponin leak’
have also been used. The terms ‘concomitant myocardial injury’
and ‘troponin positive non-ACS’ are additional possibilities. We
would prefer the term ‘secondary myocardial injury’ because
there is usually an obvious illness or acute event related to the
cardiac injury.
A descriptive term such as ‘secondary MI’ would have several
advantages over TYPE 2 MI. New, clinically relevant, myocardial
dysfunction is often not evident, and the term secondary myocar-
dial injury does not imply signiﬁcant scarring as does the term MI.
Thus, our COPD/pneumonia patient need not be told he had a
‘heart attack’ as a complication of his pneumonia. Rather, he
could be told that his blood tests indicated his heart was under
severe stress when he was sick, and (if clinically indicated)
follow-up tests may be warranted. In essence, the ﬁndings could
be treated as a positive cardiac stress test.
Adopting a descriptive approach to the new diagnostic scheme
might also help in describing the other proposed categories of MI.
As noted by the task force, problems exist when interpreting tro-
ponin elevations in other speciﬁc clinical settings apart from those
patients acutely ill from non-cardiac diseases. Surgical patients
undergoing cardiopulmonary bypass, or patients having elective
percutaneous coronary intervention (PCI) can have some bio-
marker elevation even with a very successful procedure. For
example, due to micro-emboli in the case of PCI, or direct
needle damage to myocardium in the case of coronary artery
bypass grafting (CABG). But damage (usually more severe) can
also occur due to dissection of a coronary artery (PCI), graft
occlusion (CABG), or other coronary event. As such, criteria
are needed to differentiate between relative minor injuries that
could be expected even with a successful procedure, from
damage indicative of what should clearly be considered an unde-
sirable complication of the procedure (MI).
In keeping with this reasoning, interventional cardiologists have
opted to use the less sensitive CK-MB to deﬁne MI post-PCI.
They deﬁne an MI as a complication of PCI when CK-MB increases
three or more times normal.
18 The task force has recommended
(by arbitrary convention) that PCI-related MI (TYPE 4a) be
deﬁned by a biomarker elevation greater than three times its
99th URL, assuming a normal baseline value going into the pro-
cedure. They do not say which biomarker need be used to meet
these criteria.
In either the case of PCI or CABG, the important differentiation
is to distinguish an event severe enough to be considered as a com-
plication, from relatively minor (expected) injury related to the
procedure. If criteria appropriate for the clinical setting do not
qualify for diagnosing MI, small abnormalities in cardiac biomarkers
can be ignored. However, if criteria for MI are exceeded it could
simply be termed ‘PCI complicated by MI, or ‘CABG complicated
by MI’ without the need for using speciﬁc subtype letters or
numbers. If the problems of diagnosing patients who have suffered
sudden death are considered a separate issue, this would greatly
simplify incorporation of the new diagnostic scheme into ICD-9
codes.
The preferred terminology may require further debate, but the
new scheme for the deﬁnition of MI provides an improved frame-
work for assessing and documenting coronary ischaemia/infarct.
No matter how the ICD-9 codes evolve, it makes clinical sense
to clearly differentiate between troponin elevations that are
chronic, vs. transient elevations associated with acute coronary
events, vs. transient elevations associated with other myocardial
stresses.
Making these distinctions clear may also help in our quest for
ever improving therapy. Troponin elevations are quite common
in intensive care unit patients such as the one presented
above.
10–13,19,20 The in-hospital complication rates for patients
hospitalized for ACS are high,
21 and patients who suffer acute MI
during hospitalization for other problems differ substantially in
their clinical course and outcomes compared with those who
present initially with an acute coronary syndrome.
22 The ACC/
AHA guidelines for the management of patients with unstable
angina/non-ST-elevation MI
23 promote an aggressive approach
for treatment of non-ST elevation MI, but no recommendations
are made for assessment and treatment of TYPE2 MI. This leaves
the optimal treatment strategy for such patients quite uncertain.
By providing a speciﬁc new diagnosis, it may be possible to
encourage further research on how best to manage these patients,
and perhaps help determine whether a troponin level should be
measured in the ﬁrst place.
24
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